课题基金 / 基金详情

IDO2 Targeting in Pancreatic Cancer

IDO2 Targeting in Pancreatic Cancer
IDO2 靶向治疗胰腺癌
批准号:
8965168
负责人:
GEORGE C PRENDERGAST
金额:
$40.77万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-16 至 2020-06-30

项目摘要

项目成果

GEORGE C PRENDERGAST的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(申请人提供):胰腺导管腺癌(PDAC)逃避免疫控制的机制鲜为人知,但可能会恢复以改善临床结果。我们建议的主要影响是,它解决了对治疗标志物的需求,以帮助IDO抑制剂的临床开发,IDO抑制剂是一种很有前途的新型小分子免疫疗法,目前正处于第二阶段试验。在早期的R21奖的基础上,我们将发展我们的假设,即IDO2基因可以(1)通知胰腺导管腺癌(PDAC)的发展,以及(2)基于IDO2编码区影响其酶活性的自然多态变异,定义宿主生物标记物来区分个体PDAC患者对IDO抑制剂的反应。本质上,我们的项目试图阐明PDAC发展的免疫基础,并确定可以预测IDO抑制剂在单个患者中治疗效果的治疗标志物。在我们的提案中,科学意义的一个主要来源是它如何处理“癌症相关”炎症的问题:为什么慢性炎症会导致一些人患上癌症,而不是其他人?炎症和免疫逃逸被公认为是PDAC的致病因素,但很明显,这个问题在肿瘤学中具有更广泛的普遍意义。而单曲中的变体 途径不能完全解决这个问题,我们对IDO2的关注可能会为IDO抑制剂治疗提供指导,并帮助一些具有合适IDO2基因的PDAC患者进入更可管理的状态。正是在这个意义上,我们的项目在提供改善临床治疗的机会方面是精辟的。我们的初步结果表明,IDO2编程了一个致病过程,在PDAC中实施了一种强大的免疫逃逸机制,从而许可了其快速进展和对治疗的耐药性。我们发现了IDO2,并产生了一个独特的条件遗传突变小鼠,以了解IDO2如何影响炎症性肿瘤微环境。在人类癌症中,PDAC是一个被选择的焦点,因为我们发现这种类型的癌症在免疫细胞和实体瘤细胞中都过度表达IDO2(后者在大多数肿瘤中通常不是IDO2的情况)。这一特征可能与PDAC与慢性炎症和侵袭性病理有特别强的相关性有关。目的1将继续对一组独特的PDAC患者的IDO2基因变异进行临床研究,到目前为止的初步调查表明,一组选定的PDAC患者(即晚发患者和女性患者)更有可能与WT宿主IDO2基因相关。目的2将开展一项小鼠遗传学研究,证明IDO2缺乏限制了一种对K-RAS诱导的PDAC至关重要的致病性炎症。这一目标将探索分子和细胞机制,以了解免疫细胞和肿瘤细胞中IDO2的表达如何促进恶性肿瘤的发展和治疗反应。目的3将比较自然产生的人类IDO2基因变异在小鼠体内对PDAC发展和治疗的影响的致病作用和机制贡献。这个项目提供了一个机会,利用一个杰出的、经验丰富的团队来促进IDO抑制剂的开发,用于PDAC的有效联合免疫化疗。
英文摘要
 DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) eludes immune control by mechanisms that are poorly understood but might be restored to improve clinical outcomes. The primary impact of our proposal is that it addresses the need for theranostic markers to assist the clinical development of IDO inhibitors, a promising new class of small molecule immunotherapy now in Phase II trials. Building upon an earlier R21 award, we will develop our hypothesis that the IDO2 gene can (1) inform the development of pancreatic ductal adenocarcinoma (PDAC) and (2) define a host biomarker to stratify individual PDAC patient responses to an IDO inhibitor, based on natural polymorphic variations in the IDO2 coding region that affect its enzyme activity. In essence, our project seeks to illuminate an immune basis for PDAC development and to identify a theranostic marker that could predict the efficacy of IDO inhibitor treatment in an individual patient. A major source of scientific significance in our proposal is how it approaches the question of "cancer- associated" inflammation: why does chronic inflammation lead to cancer in some individuals but not others? Inflammation and immune escape are well established as causative factors in PDAC, but it is clear that this question has broader general significance in oncology. While variations in a single pathway cannot address this question fully, our focus on IDO2 may inform IDO inhibitor therapy and help tilt some PDAC patients with a suitable IDO2 genotype into a more manageable state. It is in this sense that our project is incisive in the opportunity if offers to improve clinical treatment. Our preliminary results suggest that IDO2 programs a pathogenic process that enforces a powerful mechanism of immune escape in PDAC, thereby licensing its rapid progression and resistance to treatment. We discovered IDO2 and generated a unique conditionally genetic mutant mouse to understand how IDO2 informs the inflammatory tumor microenvironment. Among human cancers, PDAC was a chosen focus because of our discovery that this type of cancer overexpresses IDO2 in both immune cells and solid tumor cells (the latter of which is not usually the case for IDO2 in most tumors). This feature may be relevant to the particularly strong correlates of PDAC with chronic inflammation and aggressive pathology. Aim 1 will continue a clinical study of IDO2 genetic variants in a unique subset of PDAC patients, where pilot investigations to date suggest that a select set of PDAC patients (i.e., late-onset as well as female patients) are more likely to correlate with a WT host IDO2 genotype. Aim 2 will develop a mouse genetic study demonstrating that IDO2 deficiency limits a type of pathogenic inflammation that is critical for K-Ras-induced PDAC. This Aim will explore molecular and cellular mechanisms to learn how IDO2 expression in immune cells and tumor cells contribute to malignant development and treatment response. Aim 3 will compare pathogenic and mechanistic contributions of the naturally occurring human IDO2 genetic variants in the mouse, in terms of their impact on PDAC development and treatment. This project offers the opportunity to leverage an outstanding, experienced team to promote the development of IDO inhibitors for effective combination immunochemotherapy of PDAC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis
OPPC targeting to improve pancreatic cancer treatment
IDO2 Targeting for pancreatic cancer treatment
海外基金